Continuous Glucose Monitors Go Mainstream: Diabetology in 2026

Continuous glucose monitors (CGMs) used to be a tool only for type 1 diabetes. The 2024 launch of OTC CGMs (Stelo, Lingo) brought real-time glucose data to millions of T2D and prediabetic — and even non-diabetic — users. The clinical question in 2026 is what to actually do with that data.

Where CGM clearly improves outcomes

• Insulin-using diabetes — both T1D and insulin-treated T2D — improvements in time-in-range and HbA1c are robust.
• Hypoglycaemia detection — alarms prevent severe events, especially in nocturnal hypoglycaemia.
• Behavioural change in T2D — real-time post-meal data drives durable diet and activity changes in motivated patients.

Where the evidence is thinner

• Wellness use in non-diabetics — interesting data but not yet proven to improve hard outcomes; risk of over-restriction and disordered eating.
• Sport performance optimisation — popular but evidence-poor; many fitness claims are extrapolation, not proven.
• 'Glucose spikes' anxiety — normal post-meal rises are physiological; not every spike is a warning sign.

How to use a CGM well

• Anchor it to a clear question — improving HbA1c, identifying hidden hypos, or testing specific meal patterns.
• Time-in-range > 70% is the diabetes target — focus there, not on every spike.
• Discuss patterns with your clinician — CGM data without a clinical conversation often produces noise, not insight.

What this means for patients and practising clinicians

If you have diabetes — especially insulin-treated — a CGM is now standard care. If you're prediabetic or simply curious, CGM can drive real behaviour change *if* paired with a clear plan and a clinician. Without that, it can become wellness anxiety dressed as data.

*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*